Stability of Chimpanzee Adenovirus Vectored Vaccines (ChAdOx1 and ChAdOx2) in Liquid and Lyophilised Formulations

Adenovirus vectored vaccines have entered global use during the COVID-19 pandemic, and are in development for multiple other human and veterinary applications. An attraction of the technology is the suitability of the vaccines for storage at 2–8 °C for months. Widely used COVID-19 vaccine ChAdOx1 nC...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Adam Berg, Daniel Wright, Pawan Dulal, Anna Stedman, Sofiya Fedosyuk, Michael J. Francis, Bryan Charleston, George M. Warimwe, Alexander D. Douglas
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	stability vaccine formulation adenovirus Medicine R
Acceso en línea:	https://doaj.org/article/afc0a50e705742ddac58b0fa77740ec1
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:afc0a50e705742ddac58b0fa77740ec1
record_format	dspace
spelling	oai:doaj.org-article:afc0a50e705742ddac58b0fa77740ec12021-11-25T19:10:31ZStability of Chimpanzee Adenovirus Vectored Vaccines (ChAdOx1 and ChAdOx2) in Liquid and Lyophilised Formulations10.3390/vaccines91112492076-393Xhttps://doaj.org/article/afc0a50e705742ddac58b0fa77740ec12021-10-01T00:00:00Zhttps://www.mdpi.com/2076-393X/9/11/1249https://doaj.org/toc/2076-393XAdenovirus vectored vaccines have entered global use during the COVID-19 pandemic, and are in development for multiple other human and veterinary applications. An attraction of the technology is the suitability of the vaccines for storage at 2–8 °C for months. Widely used COVID-19 vaccine ChAdOx1 nCoV-19 (University of Oxford/AstraZeneca) is based on a species E simian adenovirus. Species E simian serotypes have been used in a wide range of other development programs, but the stability of such vectors has not been extensively described in the peer-reviewed literature. Here, we explore the stability of two candidate vaccines based on two species E serotypes: a Rift Valley fever vaccine based upon the ChAdOx1 vector (Y25 serotype) used in ChAdOx1 nCoV-19, and a rabies vaccine based upon a ChAdOx2 vector (AdC68 serotype). We describe each vector’s stability in liquid and lyophilised formulations using in vitro and in vivo potency measurements. Our data support the suitability of liquid formulations of these vectors for storage at 2–8 °C for up to 1 year, and potentially for nonrefrigerated storage for a brief period during last-leg distribution (perhaps 1–3 days at 20 °C—the precise definition of acceptable last-leg storage conditions would require further product-specific data). Depending upon the level of inprocess potency loss that is economically acceptable, and the level of instorage loss that is compatible with maintenance of acceptable end-of-storage potency, a previously reported lyophilised formulation may enable longer term storage at 20 °C or storage for a number of days at 30 °C.Adam BergDaniel WrightPawan DulalAnna StedmanSofiya FedosyukMichael J. FrancisBryan CharlestonGeorge M. WarimweAlexander D. DouglasMDPI AGarticlestabilityvaccine formulationadenovirusMedicineRENVaccines, Vol 9, Iss 1249, p 1249 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	stability vaccine formulation adenovirus Medicine R
spellingShingle	stability vaccine formulation adenovirus Medicine R Adam Berg Daniel Wright Pawan Dulal Anna Stedman Sofiya Fedosyuk Michael J. Francis Bryan Charleston George M. Warimwe Alexander D. Douglas Stability of Chimpanzee Adenovirus Vectored Vaccines (ChAdOx1 and ChAdOx2) in Liquid and Lyophilised Formulations
description	Adenovirus vectored vaccines have entered global use during the COVID-19 pandemic, and are in development for multiple other human and veterinary applications. An attraction of the technology is the suitability of the vaccines for storage at 2–8 °C for months. Widely used COVID-19 vaccine ChAdOx1 nCoV-19 (University of Oxford/AstraZeneca) is based on a species E simian adenovirus. Species E simian serotypes have been used in a wide range of other development programs, but the stability of such vectors has not been extensively described in the peer-reviewed literature. Here, we explore the stability of two candidate vaccines based on two species E serotypes: a Rift Valley fever vaccine based upon the ChAdOx1 vector (Y25 serotype) used in ChAdOx1 nCoV-19, and a rabies vaccine based upon a ChAdOx2 vector (AdC68 serotype). We describe each vector’s stability in liquid and lyophilised formulations using in vitro and in vivo potency measurements. Our data support the suitability of liquid formulations of these vectors for storage at 2–8 °C for up to 1 year, and potentially for nonrefrigerated storage for a brief period during last-leg distribution (perhaps 1–3 days at 20 °C—the precise definition of acceptable last-leg storage conditions would require further product-specific data). Depending upon the level of inprocess potency loss that is economically acceptable, and the level of instorage loss that is compatible with maintenance of acceptable end-of-storage potency, a previously reported lyophilised formulation may enable longer term storage at 20 °C or storage for a number of days at 30 °C.
format	article
author	Adam Berg Daniel Wright Pawan Dulal Anna Stedman Sofiya Fedosyuk Michael J. Francis Bryan Charleston George M. Warimwe Alexander D. Douglas
author_facet	Adam Berg Daniel Wright Pawan Dulal Anna Stedman Sofiya Fedosyuk Michael J. Francis Bryan Charleston George M. Warimwe Alexander D. Douglas
author_sort	Adam Berg
title	Stability of Chimpanzee Adenovirus Vectored Vaccines (ChAdOx1 and ChAdOx2) in Liquid and Lyophilised Formulations
title_short	Stability of Chimpanzee Adenovirus Vectored Vaccines (ChAdOx1 and ChAdOx2) in Liquid and Lyophilised Formulations
title_full	Stability of Chimpanzee Adenovirus Vectored Vaccines (ChAdOx1 and ChAdOx2) in Liquid and Lyophilised Formulations
title_fullStr	Stability of Chimpanzee Adenovirus Vectored Vaccines (ChAdOx1 and ChAdOx2) in Liquid and Lyophilised Formulations
title_full_unstemmed	Stability of Chimpanzee Adenovirus Vectored Vaccines (ChAdOx1 and ChAdOx2) in Liquid and Lyophilised Formulations
title_sort	stability of chimpanzee adenovirus vectored vaccines (chadox1 and chadox2) in liquid and lyophilised formulations
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/afc0a50e705742ddac58b0fa77740ec1
work_keys_str_mv	AT adamberg stabilityofchimpanzeeadenovirusvectoredvaccineschadox1andchadox2inliquidandlyophilisedformulations AT danielwright stabilityofchimpanzeeadenovirusvectoredvaccineschadox1andchadox2inliquidandlyophilisedformulations AT pawandulal stabilityofchimpanzeeadenovirusvectoredvaccineschadox1andchadox2inliquidandlyophilisedformulations AT annastedman stabilityofchimpanzeeadenovirusvectoredvaccineschadox1andchadox2inliquidandlyophilisedformulations AT sofiyafedosyuk stabilityofchimpanzeeadenovirusvectoredvaccineschadox1andchadox2inliquidandlyophilisedformulations AT michaeljfrancis stabilityofchimpanzeeadenovirusvectoredvaccineschadox1andchadox2inliquidandlyophilisedformulations AT bryancharleston stabilityofchimpanzeeadenovirusvectoredvaccineschadox1andchadox2inliquidandlyophilisedformulations AT georgemwarimwe stabilityofchimpanzeeadenovirusvectoredvaccineschadox1andchadox2inliquidandlyophilisedformulations AT alexanderddouglas stabilityofchimpanzeeadenovirusvectoredvaccineschadox1andchadox2inliquidandlyophilisedformulations
_version_	1718410236896739328

Stability of Chimpanzee Adenovirus Vectored Vaccines (ChAdOx1 and ChAdOx2) in Liquid and Lyophilised Formulations

Ejemplares similares